Editas CFO sells 453 shares in tax-plan trade

Editas Medicine’s CFO sold a small number of shares under a pre-arranged plan solely to cover tax withholding from RSU vesting, leaving a direct holding of 13,839 shares.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) reported that its SVP, Chief Financial Officer, Amy Parison, sold 453 shares of common stock on September 3, 2026 at an average price of $3.04 per share. The transaction was executed under a durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following this sale, Parison directly holds 13,839 shares of Editas Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 453 shares

Net Sell 1 txn

Insider Parison Amy

Role SVP, Chief Financial Officer

Sold 453 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	453	$3.0372	$1K

Holdings After Transaction: Common Stock — 13,839 shares (Direct)

Footnotes (1)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 453 shares Sale price per share: $3.0372 per share Shares held after transaction: 13,839 shares +3 more

6 metrics

Shares sold 453 shares Common stock sale by CFO on September 3, 2026

Sale price per share $3.0372 per share Average price for the 453 shares sold on September 3, 2026

Shares held after transaction 13,839 shares Direct ownership by CFO following the September 3, 2026 sale

Net shares sold 453 shares Net change in buy/sell activity reported in this Form 4

Plan adoption date July 7, 2022 Date durable automatic sales instruction plan was adopted

RSU vesting date September 2, 2026 Vesting that triggered tax withholding obligations covered by this sale

Key Terms

durable automatic sales instruction plan, tax withholding obligations, restricted stock units, Rule 10b5-1

4 terms

durable automatic sales instruction plan financial

"Sale was effected pursuant to a durable automatic sales instruction plan adopted"

tax withholding obligations financial

"represents the sale of shares by the Issuer necessary to meet tax withholding"

restricted stock units financial

"as a result of vesting in restricted stock units on September 2, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 regulatory

"transactions affirmed under a trading plan pursuant to Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did Editas Medicine (EDIT) report for its CFO?

Editas Medicine reported that CFO Amy Parison sold 453 shares of common stock on September 3, 2026 at an average price of $3.0372 per share under a pre-arranged automatic sales plan.

Why did the Editas Medicine (EDIT) CFO sell 453 shares?

The sale of 453 shares was made to meet tax withholding obligations resulting from the vesting of restricted stock units on September 2, 2026. The filing states that this sale does not represent a discretionary trade by the CFO.

Was the EDIT CFO’s share sale under a Rule 10b5-1 plan?

Yes. The filing affirms use of a Rule 10b5-1 trading arrangement and explains that the sale was effected pursuant to a durable automatic sales instruction plan adopted by the CFO on July 7, 2022.

How many Editas Medicine (EDIT) shares does the CFO hold after this transaction?

After selling 453 shares, CFO Amy Parison directly holds 13,839 shares of Editas Medicine common stock, according to the Form 4 disclosure.

What was the sale price in the Editas Medicine (EDIT) insider transaction?

The Form 4 reports that the 453 shares of Editas Medicine common stock were sold at an average price of $3.0372 per share in the open market or a private transaction on September 3, 2026.

Who is the reporting person in this Editas Medicine (EDIT) Form 4?

The reporting person is Amy Parison, who serves as SVP, Chief Financial Officer of Editas Medicine, Inc., as identified in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:25 PM Accepted by SEC EDGAR 09/04/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		453	D	$3.0372	13,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Amy Parison	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)